Transfusion Support After CAR-T Cell Therapy: Real-World Patterns Across Commercial Products and Disease Groups.

Authors

Jay Patel, Denise L Pereira, Damian Green, Amer Beitinjaneh, Noa G Holtzman, Mark S Goodman, Antonio M Jimenez Jimenez, Lazaros Lekakis, Jay Spiegel, Trent Wang, Claudette Gail Edwards, Cara Benjamin, Yanyun Wu, Abdulaziz F Al Mana

Published in

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. Jul 18, 2026. Epub Jul 18, 2026.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is frequently complicated by prolonged cytopenias requiring transfusion. Comparative real-world data on transfusion burden across commercial CAR-T products and post-therapy alloimmunization risk remain limited.
We retrospectively reviewed 102 patients treated with idecabtagene vicleucel (Abecma), ciltacabtagene autoleucel (Carvykti), lisocabtagene maraleucel (Breyanzi), axicabtagene ciloleucel (Yescarta), or brexucabtagene autoleucel (Tecartus) at a single center. Red blood cell (RBC) and platelet transfusions were quantified over 0-30, 30-90, and 90-180 days post-infusion. Kruskal-Wallis tests and negative binomial regression with disease-stratified interpretation were used to estimate incidence rate ratios with 95% confidence intervals. Alloimmunization was assessed through routine, clinically driven antibody screening.
Adjusted exploratory models detected no product-specific differences in RBC support. Platelet transfusion distributions varied by product and disease group, but these findings were based on small absolute counts and were driven by a minority of high-need patients; therefore, they should be interpreted as hypothesis-generating rather than definitive product-level differences. No new RBC alloantibodies were detected through routine clinical antibody screening.
Transfusion needs after CAR-T therapy were concentrated in the first 30 days and were modest overall, with most patients transfusion-free thereafter. This real-world descriptive analysis helps fill a current gap in understanding transfusion-support patterns across commercial CAR-T products and disease groups. Apparent product- and disease-related differences were driven by a minority of high-need patients and should be considered hypothesis-generating. No new RBC alloantibodies were detected through routine clinical screening, although standardized antibody surveillance was not performed.

PMID:
42471153
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.